AtaiBeckley ATAI
NASDAQ ATAI
$7.39 +0.05 (+0.75%)
As of: Sep 4, 2026 · 3:19 PM EDT

AtaiBeckley (ATAI) Cash from Financing Activities (2020 - 2026)

AtaiBeckley (ATAI) posted quarterly Cash from Financing Activities of $821000.0 for Q1 2026, down 98.62% year-over-year from $59.6 million in Q1 2025, and down 98.62% quarter-over-quarter from $59.6 million in Q1 2025.

Analysis

AtaiBeckley (ATAI) Cash from Financing Activities (2020 - 2026) Analysis & Trends

AtaiBeckley has reported Cash from Financing Activities for 6 years, with the latest figure at $59.7 million in Q3 2025.

  • Quarterly Cash from Financing Activities rose 1120.76% year-over-year to $59.7 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $127.3 million (up 4026.57% YoY) and the FY2024 annual result came in at $5.4 million, up 164.32% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $821000.0, down from $59.6 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $59.6 million in Q1 2025, with the low at $821000.0 in Q1 2026.
  • A 5-year average of $32.6 million and a median of $1.8 million in 2022 frame the typical range for Cash from Financing Activities.
  • The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities plunged 817.68% in 2023, then jumped 2279.45% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $1.7 million in 2021, then plunged by 153.51% to -$922000.0 in 2022, then slumped by 817.68% to -$8.5 million in 2023, then soared by 101.82% to $154000.0 in 2024, then surged by 38694.81% to $59.7 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered $59.7 million, $7.8 million, and $59.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.43 Bn 130.58 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.34 Bn 58.15 Bn 1.37 Bn -
4 Moderna 57.98 Bn 52.85 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn - 2.42 Bn
6 BeOne Medicines 39.92 Bn 34.82 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.42 Bn 32.11 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn - -273.15 Mn
9 Insmed 27.36 Bn 26.20 Bn 358.27 Mn 27.18 Mn
10 AtaiBeckley 1.61 Bn 1.61 Bn - 59.74 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.64 Mn
Mar 31, 2026 821,000.00
Sep 30, 2025 59.74 Mn
Jun 30, 2025 7.76 Mn
Jun 30, 2025 7.76 Mn
Mar 31, 2025 59.61 Mn
Mar 31, 2025 59.61 Mn
Dec 31, 2024 154,000.00
Sep 30, 2024 4.89 Mn
Jun 30, 2024 326,000.00
Dec 31, 2023 -8.46 Mn
Jun 30, 2023 -100,000.00
Mar 31, 2023 206,000.00
Dec 31, 2022 -922,000.00
Sep 30, 2022 19.78 Mn
Jun 30, 2022 1.79 Mn
Mar 31, 2022 132,000.00
Dec 31, 2021 1.72 Mn
Sep 30, 2021 3.88 Mn
Jun 30, 2021 373.76 Mn